Alkermes fends off generic versions of Vivitrol until 2027

Alkermes has settled a lawsuit with Teva Pharmaceuticals establishing patent protection for the opioid and alcohol dependence treatment Vivitrol (extended-release injectable suspension of naltrexone) for four more years.